Ionis Pharmaceuticals announced that the U.S. FDA has accepted for review a New Drug Application for eplontersen, an investigational antisense medicine for the treatment of people living with hereditary transthyretin-mediated amyloid polyneuropathy. The application has been given a Prescription Drug User Fee Act action date of Dec. 22, 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IONS:
- RXDX vs. IONS: Which Biotech Stock is Better?
- Ionis Pharmaceuticals price target lowered to $27 from $34 at SVB Securities
- Ionis Pharmaceuticals price target lowered to $40 from $44 at Barclays
- Ionis Pharmaceuticals sees FY23 revenue $575M, consensus $672.18M
- Ionis Pharmaceuticals reports Q4 EPS (37c), consensus (92c)